Ibrutinib, a BTK inhibitor, has been approved for the treatment of mantle cell lymphoma (MCL) and has been clinically evaluated as monotherapy or in combination in several malignancies including activated B cell-like (ABC) DLBCL (Pan et al., 2007). This evidence concerns the gene BTK and diffuse large B-cell lymphoma.